The Phase I trial is being conducted at the Princess Alexandra hospital in Brisbane and aims to create a new ‘non-antibiotic’ based treatment for H. pylori infection. If left untreated, H. pylori infection can cause gastritis (inflammation of the lining of the stomach) and can lead to further complications such as stomach ulcers. Currently, H. pylori infection is treated with two different antibiotics as well as stomach acid supressing drugs. However, side effects occur in up to 20% of patients and compliance with taking the full treatment course is a common reason for eradication failure. New treatments developed and produced by Servatus Ltd would offer people with H. pylori infection an alternative to these traditional treatments.
Servatus Ltd, which is based in Queensland, Australia, is a biopharmaceutical company developing novel treatments for a range of autoimmune, inflammatory, gastrointestinal, and dermatological conditions. The company has two main streams of drug development and research: engineered proteins selected for their immune-modulating activity to treat immune-mediated inflammatory diseases, and pharmaceutical-grade live microbial biotherapeutic treatments, such as the one developed for the treatment of H. pylori infection.
Servatus is developing alternatives to antibiotic-based treatments so they can help to reduce the occurrence of antibiotic resistance to common bacterial pathogens, whilst also providing safe and highly effective treatments to patients in which further disturbances to the microbiome are avoided.